MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics is well positioned because agenT-797 targets ARDS, a large ICU indication with approximately 10% of admissions, hospital mortality estimated at 35% to 46%, and no FDA-approved pharmacological therapies, creating a clear unmet need for a differentiated immunotherapy. The lead asset has already shown encouraging early clinical signals, including 70% 30-day survival in a Phase 1/2 study versus about 10% in contemporaneous controls, no CRS or ICANS, and favorable reductions in secondary bacterial pneumonia, supporting confidence in the ongoing randomized Phase 2b/3 program that began in May 2026. Its off-the-shelf, HLA-independent, no-lymphodepletion manufacturing model, plus additional optionality from oncology, transplantation, and ARPA-H support, strengthens the investment case by combining scalable economics with multiple future catalysts.

MiNK Therapeutics is facing a fundamentally challenged profile because its lead allogeneic iNKT platform still lacks proven regulatory precedent, and the FDA has not yet agreed that the seamless Ph2b/3 design is registrational. With only about $8.8 million in cash and cash equivalents as of June 30, 2026, it likely needs additional capital within the next 12 months, raising dilution risk before profitability is visible. Even if agenT-797 succeeds clinically, commercialization remains uncertain because physicians and payors may resist adoption, reimbursement for ARDS has no drug precedent, and competition could undercut its market opportunity.